Medtronic touts 3-year data for Evolut TAVR

Medtronic (NYSE:MDT) announced three-year data supporting its Evolut transcatheter aortic valve replacement (TAVR) system.

Related Keywords

John Forrest ,Corevalve Evolut ,Medtronic Evolut ,Nina Goodheart ,World Heart Federation Congress ,Yale School Of Medicine ,Journal Of The American College Cardiology ,American College Of Cardiology ,Medtronic ,Evolut Low Risk ,American College ,Annual Scientific Session Together ,World Heart Federation ,World Congress ,Yale School ,Evolut Low Risk Trial ,Structural Heart ,